FindTrial
Sign In

Clinical, biochemical and liver tissue changes in Hepatitis-B Gray zone patients and determine eligibility for treatment thereof.

Phenotype, clinical profile and treatment eligibility of Hepatitis-B infected patients lying in gray zone in a tertiary care center of Eastern India - an observational study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/12/060743
Enrollment
350
Registered
2023-12-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B181- Chronic viral hepatitis B withoutdelta-agent

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

I.P.G.M.R, Kolkata
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Hepatitis B patients 1. Age > 18 years 2. Fulfilling Gray zone criteria a) Grey zone A (GZ- A): HBeAg positive, normal ALT levels and serum HBV DNA b) Grey zone B (GZ- B): HBeAg positive, elevated ALT levels and serum HBV DNA c) Grey zone C (GZ- C): HBeAg negative, normal ALT levels and serum HBV DNA d) Grey zone D (GZ- D): HBeAg negative, elevated ALT levels and serum HBV DNA >2 × 10 3 IU/ml.

Exclusion criteria

Exclusion criteria: 1. subjects unwilling to give consent 2. subjects on treatment or features of Cirrhosis

Design outcomes

Primary

MeasureTime frame
Liver stiffness measure and histopathological changes (Liver Biopsy)Timepoint: At baseline—

Secondary

MeasureTime frame
NoneTimepoint: Not Applicable—

Countries

India

Contacts

Public ContactDr Abdullah Md Hasan

IPGMER and SSKM hospital, Kolkata

abdullah86alamin@gmail.com9474174717

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026